Background: Allergic rhinitis (AR) carries a high symptom burden and impact on quality of life. The ability of an AR treatment to achieve and sustain symptom suppression would be expected to enhance quality of life and improve long-term outcomes. Methods: In this ad hoc analysis of data from 4 phase 3 clinical trials of mometasone furoate nasal spray (MFNS), subjects with perennial AR recorded the severity of nasal symptoms twice daily for 12 weeks on a 4-point scale to determine the total nasal symptom score. Results: In the pooled sample of 1,149 subjects, 580 received MFNS 200 µg per day and 569 received placebo. Significantly more subjects receiving MFNS achieved symptom suppression versus those receiving placebo: 63.3% (n = 367) versus 51.0% (n = 290; p < 0.001). Median time to suppression was significantly shorter with MFNS versus placebo (29 vs. 59 days; p < 0.001). Total suppression was achieved in a significantly greater percentage of patients receiving MFNS versus placebo (36.0 vs. 25.5%; p < 0.001). Conclusions: A high level of symptom relief is attained faster and sustained longer with MFNS. This analysis validates the importance of treatment adherence to achieve optimal, sustained symptom relief.

1.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O’Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D, World Health Organization, GA2LEN, AllerGen: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008;63(suppl 86):8–160.
2.
Schatz M: A survey of the burden of allergic rhinitis in the USA. Allergy 2007;62(suppl 85):9–16.
3.
Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC: A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(suppl 85):17–25.
4.
Drouin M, Yang WH, Bertrand B, Van Cauwenberge P, Clement P, Dalby K, Darnell R, Ernst TM, Hébert J, Karlsson G, Luciuk G, Mazza J, Roovers M, Ruoppi P, Seppey M, Stern M, Suonpää J, Sussman G, Tan KY, Tse K, Widjaja P, Jensen P, Nolop K, Lutsky BN: Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996;77:153–160.
5.
Mandl M, Nolop K, Lutsky BN: Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol 1997;79:370–378.
6.
Chervinsky P, Gopalan G, Gates D: Mometasone furoate nasal spray is effective for treatment of mild-to-moderate perennial allergic rhinitis. J Allergy Clin Immunol 2009;123(suppl 2):S133.
7.
Georgitis JW: Nasal hyperthermia and simple irrigation for perennial rhinitis: changes in inflammatory mediators. Chest 1994;106:1487–1492.
8.
Li H, Sha Q, Zuo K, Jiang H, Cheng L, Shi J, Xu G: Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children. ORL J Otorhinolaryngol Relat Spec 2009;71:50–55.
9.
Tano L, Tano K: A daily nasal spray with saline prevents symptoms of rhinitis. Acta Otolaryngol 2004;124:1059–1062.
10.
Loh CY, Chao SS, Chan YH, Wang DY: A clinical survey on compliance in the treatment of rhinitis using nasal steroids. Allergy 2004;59:1168–1172.
11.
Ferguson C, Ohayon JA: Real life attitudes toward treatment of pediatric allergic rhinitis (abstract 72). Poster presented at: Canadian Paediatric Society’s 81st Annual Meeting, Montreal, 2004. http://www.pulsus.com/cps2004/abs/abs072.htm.
12.
Allergies in America: Executive summary. http://www.myallergiesinamerica.com (accessed 2009).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.